Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.
Related news for (BIOR)
- biora therapeutics announces $3 million registered direct offering priced at-the-market under nasdaq rules
- biora therapeutics shares progress on smaller biojet™ clinical device with largest payload of any ingestible injectable at the 14th annual podd meeting
- biora therapeutics to reveal 00-size biojet™ device at the 14th annual partnership opportunities in drug delivery meeting
- biora therapeutics to present at the 19th annual peptide therapeutics symposium
- biora therapeutics announces award-winning abstract to be presented at american college of gastroenterology annual scientific meeting 2024